Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 157
HOS-214907 · Präparat HOS-155350
Blood and lymphatic system disorders Very common: Haematological toxicity was increased in patients receiving trastuzumab and docetaxel, compared with docetaxel alone (32% grade 3/4 neutropenia versus 22%, using NCI-CTC criteria). Note that this is likely to be an underestimate since docetaxel alone at a dose of 100 mg/m2 is known to result in neutropenia in 97% of patients, 76% grade 4, based on nadir blood counts. The incidence of febrile neutropenia/neutropenic sepsis was also increased in patients treated with Herceptin plus docetaxel (23% versus 17% for patients treated with docetaxel alone).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 9d27ae265d7b9ef0a82076e86678d74812dd5dd2a987c0161e40bcdab81b10fc · Zeichen 18986–19590 im Abschnitt